Key result
Warfarin triggers skin necrosis despite therapeutic LMWH bridging in pulmonary embolism case.
Why the study?
Coumadin-induced skin necrosis is a rare complication that can occur despite low molecular weight heparin bridging therapy, requiring clinical recognition and management.
Case Report (n=1)
Highlights a rare case of coumadin-induced skin necrosis occurring despite appropriate LMWH bridging therapy.
Warrants vigilance for early skin necrosis with warfarin initiation; extends limited case literature on this rare event.
BACKGROUND: Coumadin is the standard oral anticoagulant used in a variety of clinical conditions. Coumadin inhibits the vitamin-K dependent gamma-carboxylation of coagulation factors II, VII, IX, X and the anticoagulant proteins C and S. Rarely, skin necrosis occurs when the resultant initial procoagulant state in the first few days of starting coumadin leads to thrombosis and formation of blood clots tin the dermal capillaries. This in turn causes skin necrosis due to interruption in blood supply to the skin. CASE REPORT: We are presenting the case of a 64 year-old female admitted for acute respiratory distress secondary to newly-diagnosed pulmonary embolism. The patient was started on therapeutic doses of low molecular weight heparin (LMWH) and coumadin. After 5 days of treatment, the patient started complaining of pain and numbness in both upper extremities. Overnight, this rapidly progressed to manifest hemorrhagic bullae with necrotic areas. This was immediately recognized as coumadin-induced skin necrosis. Coumadin was stopped immediately. Vitamin K was administered and local wound care was provided. Therapeutic LMWH was continued. The skin lesions began to show improvement after 3 days. CONCLUSIONS: In coumadin-induced skin necrosis, the patient initially presents with pain and erythema, followed by petechial lesions which progress to become purpuric. Hemorrhagic bullae with necrosis and eschar formation may soon develop. Once it is suspected, coumadin should be stopped and the patient should be given Vitamin K and FFP to reverse the effects of coumadin.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2012) conducted a case report in Coumadin-induced skin necrosis (n=1). Coumadin and LMWH was evaluated on Development of skin necrosis. A 64-year-old female developed coumadin-induced skin necrosis after 5 days of treatment for pulmonary embolism, despite receiving therapeutic low molecular weight heparin bridging therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: